Protagonist Therapeutics (PTGX)

12.18 +0.66 (5.73%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (6/7/19 *Est.)

Latest Headlines

Form S-8 Protagonist Therapeutics March 12, 2019 8:53 PM - SEC Filing Form 10-K Protagonist Therapeutics For: Dec 31 March 12, 2019 4:28 PM - SEC Filing Form 8-K Protagonist Therapeutics For: Mar 12 March 12, 2019 4:08 PM - SEC Filing Protagonist Therapeutics (PTGX) Misses Q4 EPS by 10c, Revenues Miss March 12, 2019 4:05 PM - StreetInsider Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results March 12, 2019 4:01 PM - PR NewsWire William Hodder Joins Escient Pharmaceuticals as Chief Business Officer March 12, 2019 7:30 AM - BizWire Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results March 5, 2019 7:00 AM - PR NewsWire Form 4 Protagonist Therapeutics For: Feb 28 Filed by: Liu David Y March 4, 2019 6:36 PM - SEC Filing Form 4 Protagonist Therapeutics For: Feb 28 Filed by: PATEL DINESH V PH D March 4, 2019 6:34 PM - SEC Filing Form 4 Protagonist Therapeutics For: Feb 28 Filed by: Saks Samuel R March 4, 2019 6:33 PM - SEC Filing Form 4 Protagonist Therapeutics For: Feb 28 Filed by: Shames Richard S. March 4, 2019 6:30 PM - SEC Filing Form 4 Protagonist Therapeutics For: Feb 28 Filed by: Gupta Suneel March 4, 2019 6:28 PM - SEC Filing BMO Capital Starts Protagonist Therapeutics (PTGX) at Outperform February 21, 2019 5:05 PM - StreetInsider Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28 February 21, 2019 7:01 AM - PR NewsWire Form SC 13G/A Protagonist Therapeutics Filed by: PERCEPTIVE ADVISORS LLC February 14, 2019 5:21 PM - SEC Filing Form SC 13G/A Protagonist Therapeutics Filed by: GREAT POINT PARTNERS LLC February 14, 2019 4:37 PM - SEC Filing Form SC 13G/A Protagonist Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P February 14, 2019 4:20 PM - SEC Filing Form SC 13G/A Protagonist Therapeutics Filed by: FARALLON CAPITAL MANAGEMENT LLC February 14, 2019 6:25 AM - SEC Filing Form SC 13G/A Protagonist Therapeutics Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C. February 13, 2019 1:45 PM - SEC Filing Form SC 13G/A Protagonist Therapeutics Filed by: FMR LLC February 13, 2019 12:10 PM - SEC Filing Form 4 Protagonist Therapeutics For: Feb 06 Filed by: PATEL DINESH V PH D February 8, 2019 5:39 PM - SEC Filing Form 4 Protagonist Therapeutics For: Feb 06 Filed by: Liu David Y February 8, 2019 5:31 PM - SEC Filing Form 4 Protagonist Therapeutics For: Feb 06 Filed by: Shames Richard S. February 8, 2019 5:28 PM - SEC Filing Form SC 13G/A Protagonist Therapeutics Filed by: Aisling Capital IV, LP February 5, 2019 4:08 PM - SEC Filing Form SC 13G/A Protagonist Therapeutics Filed by: CANAAN X L.P. January 24, 2019 1:09 PM - SEC Filing Form 4 Protagonist Therapeutics For: Jan 15 Filed by: Gupta Suneel January 16, 2019 6:43 PM - SEC Filing Protagonist Therapeutics Reports Granting of Inducement Award January 16, 2019 4:30 PM - PR NewsWire Form 3 Protagonist Therapeutics For: Jan 11 Filed by: Murphy Niall January 14, 2019 8:31 PM - SEC Filing Form 4 Protagonist Therapeutics For: Jan 11 Filed by: PATEL DINESH V PH D January 14, 2019 7:00 PM - SEC Filing Form 3 Protagonist Therapeutics For: Jan 07 Filed by: Gupta Suneel January 9, 2019 6:09 PM - SEC Filing Protagonist Therapeutics (PTGX) Commences Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for Treatment of Patients with Beta Thalassemia January 9, 2019 7:02 AM - StreetInsider Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia January 9, 2019 7:00 AM - PR NewsWire Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology January 7, 2019 7:00 AM - PR NewsWire Protagonist Therapeutics (PTGX) CFO to Resign December 31, 2018 4:29 PM - StreetInsider Form 8-K Protagonist Therapeutics For: Dec 21 December 31, 2018 4:22 PM - SEC Filing Full Article List